Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
1 Department of Epidemiology, Second Military Medical University, Shanghai, China 2 Department of Acute Infectious Diseases, Center for Disease Control and Prevention, Shanghai, China 3 Department of Infectious Diseases, The 1st Affiliated Hospital,

Hepatitis C virus entry: possible targets for therapy
Institute for Biomedical Research, University of Birmingham, Birmingham, UK Correspondence to: Professor J A McKeating, Institute for Biomedical Research, The Medical School, Vincent Drive, Birmingham B15 2TT, UK; j.a.mckeating@bham.ac.uk The first 150

Hepatitis A outbreak spreads at Consolidated School
Other cases possible Today's most viewed articles Was it really 'obvious' McKey would win ?America?s Next Top Model?? - 11/19/2008 Police: Second worker stole thousands from York business - 11/19/2008 Hugh Jackman robs Christian Bale of 'Sexiest

UPDATES AND COMMENTARY RSS Feed

Who Will Respond to Hepatitis C Treatment
The relatively new field of proteomics may be able to predict who will respond to Hepatitis C therapy - before treatment even begins....

Antivirals Combined Without Interferon: New Trial
Three companies unite to begin an innovative Hepatitis C trial, where two oral antiviral drugs will be combined in the absence of interferon....

HCV May Be Able to Be Cleared from Both Blood and Liver
Viral clearance doubled in a Hepatitis C Phase II trial during standard therapy when coupled with GlobeImmune's GI-5005. Because Hepatitis C must be eradicated not just from the blood, but also the liver, GI-5005's ability to speed the clearance rate...

Liver 1996 Aug;16(4):248-54

Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C.

Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, Pozzi M, Arosio V, Boari G, Fiorelli G

Istituto di Scienze Biomediche, Cattedra di Medicina Interna, Ospedale S. Gerardo dei Tintori, Monza e Universita degli Studi di Milano, Italy.

We studied 81 patients with chronic hepatitis C to investigate the relationship between iron and alpha-interferon response. Sixty-one patients (group A) were given alpha-interferon irrespective of iron status, whereas 20 (group B) with iron overload, were iron depleted before alpha-interferon therapy. In group A, 21 patients responded to alpha-interferon and 40 were non-responders. Increased iron indices were significantly more frequent in non-responders than responders. Multivariate analysis showed that among the independent variables evaluated, only gamma-GT and liver iron concentration predicted therapy outcome. After phlebotomy treatment, serum alanine aminotransferase fell significantly both in patients of group B (196 +/- 122 IU/l vs 82 +/- 37 IU/l, p < 10(-6)) and in 12 non-responders of group A (198 +/- 89 IU/l vs 107 +/- 81 IU/l, p < 10(-6)). In 16 iron depleted patients, eight from each group, subsequent treatment with alpha-interferon produced a response in only one patient. These results suggest that increased liver iron is a negative prognostic factor for alpha-interferon response in chronic hepatitis C. Iron depletion had a beneficial effect on serum alanine aminotransferase in all the patients treated, but did not improve the response to alpha-interferon.

PMID: 8877995, UI: 97032099

table Of Contents

Hepatitis Central

http://hepatitis-central.com

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 20 Nov 2008